[The effectiveness of lamotrigine in a case of ring chromosome 14 with refractory epilepsy]

Kazunori Ogawa1, Kuniaki Iyoda

  • 1Department of Child Neurology, Hiroshima City Hospital Hiroshima. ogawa4363@mtb.biglobe.ne.jp

Insights

A child with mosaic ring chromosome 14 experienced intractable seizures and developmental delay. Treatment with lamotrigine effectively controlled seizures, highlighting the importance of genetic analysis in pediatric epilepsy.

Area of Science:

  • Genetics
  • Neurology
  • Pediatrics

Background:

  • Chromosomal abnormalities can manifest as neurological disorders in children.
  • Early identification and genetic analysis are crucial for diagnosing complex pediatric conditions.

Observation:

  • A 25-month-old boy presented with intractable seizures and developmental retardation starting at six months of age.
  • Electroencephalograms (EEGs) showed focal spikes and fast activity in the right occipital region.
  • Chromosome analysis revealed a mosaic ring chromosome 14 and monosomy 14.

Findings:

  • The patient exhibited refractory partial seizures, developmental delay, and acquired microcephaly, consistent with ring chromosome 14 characteristics.
  • Despite no MRI abnormalities or congenital malformations, genetic analysis identified a chromosomal abnormality.
  • Add-on therapy with a low dose of lamotrigine completely suppressed refractory seizures.

Implications:

  • This case underscores the significance of chromosomal analysis in pediatric patients with unexplained developmental delay and refractory epilepsy.
  • Lamotrigine demonstrates efficacy in managing seizures associated with ring chromosome 14.
  • Further research is needed to establish consistent clinical characteristics of ring chromosome 14.

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.4K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.8K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K